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ABSTRACT

MECHANISM OF INTERACTION OF PEPTIDE MODIFIED NANOPARTICLES
WITH PORPHYROMONAS GINGIVALIS
Ankita Jain
November 30, 2016

Studies suggest that P. gingivalis functions as a keystone pathogen and interacts
with primary colonizers in the supragingival biofilm such as S. gordonii. This
interaction contributes to the initial colonization of the oral cavity by P. gingivalis
and thus represents a potential target for therapeutic intervention. We have
identified a peptide (BAR) derived from the streptococcal SspB protein that
functions to inhibit P. gingivalis adherence to S. gordonii. In addition, we showed
that nanoparticles (NPs) functionalized with BAR inhibit this interaction more
potently than free soluble peptide, possibly by promoting interaction with P.
gingivalis at higher valency than free peptide and increasing the avidity of the
interaction. Two approaches were used to assess the valency of BAR- P.
gingivalis interaction. First NPs were conjugated with various defined amounts of
BAR. The resulting NPs were tested for inhibition of P. gingivalis adherence
using a two-species biofilm model and the results were compared with inhibition
by free peptide. Nanoparticle preparations were synthesized in the presence of
v

increasing amounts of fluorescently labeled or unlabeled BAR. We found that
peptide bound to nanoparticles increased in a dose dependent manner ranging
from 1.20 µg BAR/mg of NPs to 5.87 µg BAR/mg of NPs. We tested them for
inhibition in the biofilm assay. We observed dose-dependent efficacy based on
the amount of BAR peptide on the nanoparticle surface. Valency of BAR peptide
directly correlated to increased inhibition. Second, inhibition of adherence was
also determined using BAR-antibody fusion proteins in dimer and tetramer form.
Peptide-antibody fusions were produced using a plant based production platform
and tested as above. We designed nucleic acid constructs that encoded BARantibody fusion proteins containing two or four molar equivalents of BAR. The
fusion protein containing two equivalents of BAR was successfully expressed
whereas the protein containing 4 BAR equivalents appeared to be toxic to cells
expressing the protein. The fusion protein containing two BAR molecules showed
a dose-dependent increase in the percent inhibition as the amount of the BAR
peptide increased However, the Ab-BAR fusion peptide was not more potent
than soluble BAR peptide. Increasing the valency of the BAR-P. gingivalis
interaction may pave the way for development of more potent therapeutics that
target the initial colonization of the oral cavity by P. gingivalis.
.
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CHAPTER 1
INTRODUCTION

Periodontitis is one of the most ubiquitous diseases and is characterized by the
destruction of connective tissue and dental bone support following an
inflammatory host response secondary to infection by periodontal bacteria
(AlJehani, 2014). It is the most common disease of the oral cavity, affecting soft
and hard structures that support the teeth, and has many clinical outcomes
including loss of attachment, bone loss and eventually tooth loss (Albandar,
2011; Dhadse et al, 2010). Periodontitis is second only to dental caries as a
cause of tooth loss among adults in developed countries (Gautam et al., 2011). A
study entitled Prevalence of Periodontitis in Adults in the United States: 2009 and
2010 estimates that 47.2 percent of the American adults or 64.7 million
Americans have mild, moderate or severe periodontitis (Eke et al., 2015). In
adults, 65 years and older, the prevalence rate increases to 70.1 percent ( Eke et
al., 2015). Other studies have demonstrated that mild forms of periodontitis affect
75% of adults in the United States and more severe forms affect 20 to 30% of
adults (Dhadse, et al, 2010). A study conducted combined the data from the
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2009 to 2010 and 2011 to 2012 cycles of the National Health and Nutrition
Examination Survey (NHANES). It concluded high prevalence of periodontitis in
US adults aged ≥30 years, with almost fifty-percent affected (Eke et al., 2015). In
the early stage of periodontitis, termed gingivitis, gums become swollen and red
due to inflammation, which is the body's natural response to the presence of
harmful bacteria. The colonization of bacteria in the supragingival area initiates
an inflammatory response which leads to periodontitis (Brogden & Guthmiller,
2002; Dickinson et al., 2011). Currently, treatments like removal of dental plaque,
antibiotic therapy or gingival surgery (if required) may help to cure periodontitis.
No therapeutic method has been devised to actually prevent the colonization of
bacteria, thereby, preventing biofilm formation.

Biofilm
A biofilm is a structured community of micro-organisms that is adhered to a
surface and enclosed in a self-generated matrix (consisting of carbohydrate
polymers, proteins, and DNA) (Donlan, 2002). Microbial biofilms are known to
cause a number of infectious diseases in humans, a few of which include
tonsillitis, dental disease, urinary tract infections and endocarditis (Bjarnsholt,
2013). Dental plaque is a complex oral multispecies biofilm that adheres to
the teeth and consists of many species of both fungal and bacterial cells.
According to World Health Organization, it is a specific but highly variable
structural entity resulting from sequential colonization and growth of
microorganisms on the surfaces of teeth and/or restorations (Rosan & Lamont,
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2000). The biofilm consists of microorganisms of various species embedded in
an extracellular matrix composed of bacterial metabolic products and substances
from serum, saliva and blood. This accumulation of microorganisms subjects the
teeth and gingival tissues to high concentrations of bacterial metabolites, often
resulting in gingivitis and eventually periodontitis. Therefore, understanding the
development of dental plaque and the corresponding etiology of periodontitis
would help to develop therapeutics to prevent or cure periodontitis.

Development of Dental Plaque
The formation of biofilms occurs in a multistep progression (O'Toole et al, 2000).
Obtaining a better understanding of the mechanisms of bacterial attachment and
co-adhesion could lead to strategies to control or influence the pattern of biofilm
formation. Distinct stages in plaque formation include the following stages
depicted in Figure 1 (Chandki et al, 2011; Dickinson et al., 2011; Marsh, 2006)

Figure 1: Stages in biofilm formation. * adapted from wikipedia.org/wiki/File:Biofilm.jpg

Plaque formation begins with the formation of the acquired pellicle (Diaz et al.,
2006). The pellicle is a thin coating of salivary proteins that adheres to the tooth
3

surface within minutes after tooth eruption or cleaning (Armstrong, 1968). The
pellicle is composed of albumin, glycoproteins, acidic proline-rich proteins,
mucins, cell debris, amylase, lysozyme and sialic acid (Lindh et al, 2014). The
pellicle provides a sticky base to support further microbial colonization (Lindh et
al., 2014). Acidic phosphoproteins and proline-rich proteins mediate initial
interactions with primary colonizing organisms, which are comprised largely of
Gram-positive cocci, including streptococcal species (Marsh, 1994; Marsh,
2006).
After pellicle formation, reversible adhesion contributes to the beginning of
bacterial cell attachment (Garrett et al, 2008). Reversible adhesion involves weak
long-range physicochemical interactions between the cell surface and the
pellicle, which can lead to stronger adhesin-receptor mediated attachment
(Garrett et al., 2008). Reversible adhesion is initiated with a single cell adhering
to the surface from a ‘planktonic’ state, in which the bacteria are freely floating in
the solution that bathes the oral cavity (Garrett et al., 2008). This change from
the ‘planktonic’ state is usually associated with the change in the expression of
genes and also the phenotype leading to the adaptation of bacterial cell lifestyle
from the planktonic environment to the environment on the tooth surface.
After reversible adhesion, the cells start to proliferate and form microcolonies.
This process may increase the diversity of the biofilm through co-adhesion
between different species (Grenier, 1992; Kinder & Holt, 1989; Kolenbrander &
Andersen, 1989). This results in the attachment of secondary colonizers to
already adhered cells. Co-adhesion is driven by specific receptor-ligand
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interactions that allow new bacterial colonizers to adhere to the previously
attached cells and results in increased complexity of the microbial community
(Grenier, 1992; Kinder & Holt, 1989; Kolenbrander & Andersen, 1989).
At this stage, the microcolonies begin to produce an extracellular matrix
comprised of extracellular carbohydrates and genomic DNA. The microcolonies
continue to proliferate and develop into ‘mature biofilms’ that are characterized
by vertical growth on the solid surface. The mature biofilm is a complex structure
comprised of towering microcolonies interspersed with fluid filled channels, which
provide nutrients and oxygen that are required for normal bacterial growth. The
channels are also conduits that facilitate the outward movement of bacterial
metabolites, waste products, and enzymes.
This biofilm life cycle is completed by the release of the bacterial cells back into
the ‘planktonic’ state either by an ‘active’ or ‘passive’ process, known as
detachment. In the active process, the cell itself may produce enzymes that
cleave the matrix, reducing the integrity of the matrix and facilitating the release
of cells. Alternatively, cells in the biofilm may stop production of enzymes that
produce the matrix. Thus the biofilm may become exposed and disintegrates. In
addition, ‘passive’ processes may also lead to the release of bacterial cells into a
free floating state, which can then recolonize a new surface. For example, the
physical abrasion of the tongue against the tooth may facilitate biofilm removal.
During the process of biofilm formation, quorum sensing and other signal
transduction pathways play an important role in biofilm growth and maturation.
For example, the process by which bacterial cells adhere and interact with a
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surface can initiate new genetic programs, allowing the microorganism to survive
in the new environment (Blango & Mulvey, 2009). This is called ‘contactdependent signaling’. Contact dependent signaling can also occur between two
different organisms. This interspecies adherence can stimulate new genetic
programs that allow cells to alter their genetic profiles to enhance viability in the
microbial community (Blango & Mulvey, 2009).

Significance of Etiology of Periodontitis
Some of the bacteria that contribute to the oral microbiotic community include
Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola
(Suzuki et al, 2013). These species are considered ‘periodontopathogens’, and
are classified as ‘red’ complex oral bacteria that have a strong association with
each other and with diseased sites in chronic adult periodontitis (Darveau et al,
2012; Suzuki et al., 2013). Two main hypotheses may explain the role of plaque
bacteria in a diseased individual. The “Specific Plaque Hypothesis” asserts that
only specific species are involved in causation of disease, even if present in low
abundance (Hajishengallis, 2014; Hajishengallis & Lamont, 2012; Loesche, 1992;
Rosier et al, 2014). One of the ‘red complex’ bacteria, P. gingivalis, has been
described to function as a keystone pathogen (Hajishengallis & Lamont, 2012;
Rocas et al., 2001; Rosier et al., 2014). It disrupts host-microbe homeostasis in
the oral cavity leading to dysbiosis even in low abundance, and is thus strongly
associated with adult periodontitis (Hajishengallis & Lamont, 2012). Given this
impact at low abundance, it is believed that P. gingivalis alters the host response
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and induces changes in microbial biofilm populations, prompting uncontrolled
inflammation and tissue damage (Darveau, 2010; Hajishengallis & Lamont, 2012;
Loesche, 1992). However, this hypothesis cannot completely explain the
absence of presumed pathogens in some diseased individuals or the presence of
these pathogenic organisms in healthy patients (Darveau, 2010). Contrary to this,
the "Non-Specific Plaque Hypothesis" proposes that periodontitis is a result of
the overall interaction of the plaque microflora with the host (Hajishengallis &
Lamont, 2012; Rosier et al., 2014). It is well established that plaque-mediated
diseases have a multi-factorial etiology and a variety of organisms are involved in
its progression (Hajishengallis & Lamont, 2012; Rosier et al., 2014). Considering
both theories, a modified hypothesis has been proposed suggesting that changes
in environmental factors lead to a shift in the resident microflora resulting in
microbial dysbiosis (Rosier et al., 2014). This modified hypothesis supports the
occurrence of potentially pathogenic species as minor members of the resident
plaque microflora (Rosier et al., 2014). Certain low-abundance microbial
pathogens can cause inflammatory disease by interfering with the host immune
system and remodeling the microbiota (Hajishengallis & Lamont, 2012; Rosier et
al., 2014). In healthy individuals, these organisms would be weakly competitive
and significantly suppressed by intermicrobial antagonism (Hajishengallis &
Lamont, 2012; Rosier et al., 2014). As such, they would comprise only a small
percentage of the plaque microflora and would have limited clinical significance
(Rosier et al., 2014).
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P. gingivalis and its interaction pattern
Apart from being considered a keystone pathogen, P. gingivalis has long been
associated with periodontitis, has a well-characterized population structure, and
demonstrates the “easiest” growth and genetic manipulation of the three ‘red
complex’ bacteria (Rocas et al., 2001). Due to these factors, P. gingivalis has
garnered much attention and has been well-studied (Curtis et al., 2011; Darveau
et al., 2012; Lamont & Jenkinson, 1998). P. gingivalis is a pathogen whose
primary niche is in the anaerobic environment of subgingival dental plaque;
however, initial colonization occurs on supragingival surfaces that already
support robust biofilm communities in oral cavity (Daep et al., 2006). Studies
suggest that biofilm formation occurs subsequent to initial adherence of P.
gingivalis to S. gordonii cells deposited on the salivary pellicle (Cook et al.,
1998). The interaction between P. gingivalis and S. gordonii is one of the many
critical interactions which promote biofilm formation. Targeting this particular
interaction may inhibit the biofilm formation more effectively, if not completely.
The commensal species S. gordonii provide an attachment substrate for
colonization and biofilm accretion by the potential pathogen, P. gingivalis (Cook
et al., 1998). Due to this favorable interaction, P. gingivalis, has been shown to
specifically adhere to primary colonizing bacteria such as S. gordonii (Park et al.,
2005). Considering this, the initial colonizing mechanism of P. gingivalis is a
primary target to inhibit biofilm formation with rationally designed therapeutics
that prevent initial supragingival colonization (Daep et al., 2006).
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BAR Peptide
P. gingivalis is a leading pathogen implicated in chronic adult periodontitis
(Koziel et al., 2014). Previous studies have shown that P. gingivalis adheres to S.
gordonii through the interaction of the minor fimbrial antigen, Mfa1, with a specific
region of the streptococcal SspB polypeptide which has been designated BAR
(SspB Adhering Region) (Chung et al., 2000; Daep et al., 2006; Daep et al.,
2008; Demuth et al., 2001; Lamont et al., 2002). It has been shown that a
synthetic peptide comprising the BAR sequence potently inhibits P. gingivalis
adherence to S. gordonii (IC50=1.3 µM) (Daep et al., 2006; Daep et al., 2008;
Daep et al., 2011). Moreover, BAR peptide significantly reduced P. gingivalis
virulence in mice that harbor S. gordonii when administered simultaneously with
P. gingivalis cells (Daep et al., 2011). However, the effects of BAR administration
demonstrated transient effects, and exhibited weaker potency against preexisting or more complex biofilms. In more complex biofilms, the IC50 increased
to 3.6 µM and an exposure time of more than 60 minutes was required to achieve
equivalent effects as achieved in two species biofilms (Demuth, unpublished).
These limitations to clinical translation spurred the need to develop novel
approaches to deliver BAR peptide at higher localized concentrations to increase
efficacy. Our recent studies suggested that poly (lactic-co-glycolic acid) (PLGA)
nanoparticles (NPs) that are surface-functionalized with BAR inhibit P. gingivalis
and S. gordonii interactions more potently than free soluble peptide (SteinbachRankins and Demuth, unpublished).

9

Advantages of Nanoparticles as advanced therapeutics
Nanoparticles are being studied extensively as a delivery method for
antimicrobials for various diseases (De Jong & Borm, 2008; McMillan, Batrakova
et al., 2011; Singh & Lillard, 2009). They offer many advantages over
conventional therapeutic approaches that deliver free antimicrobials via oral,
submucosal, or localized delivery routes (Gelperina et al., 2005; Ikuma et al.,
2015; Singh & Lillard, 2009). First, due to their small size, NPs can penetrate
barriers to deliver higher concentrations of active agents at target sites, providing
increased efficacy (Mudshinge et al. , 2011; Singh & Lillard, 2009). Second, NPs
can be tailored to recognize specific cell types simply by altering their surfacechemistry (Mudshinge et al., 2011; Singh & Lillard, 2009). Moreover, NPs allow
for prolonged delivery of drugs which helps to increase the efficacy of the drugs
for increased durations under often adverse physiological conditions in vivo
(Hong et al., 2007; Puglia et al., 2008; Singh & Lillard, 2009). Also, NPs may
promote multivalent binding which can act to increase the potency of active
agents (Hong et al., 2007). In addition to this, NPs promote the stability of active
agents in vivo, by protecting the agent from degradation. Apart from these
advantages, NPs can carry a diversity of hydrophilic and hydrophobic active
agents (e.g. drugs, proteins, peptides, genes, etc.) that can be co-incorporated in
the NP matrix and can be administered orally, locally and intravenously (Mody et
al., 2010; Mudshinge et al., 2011; Singh & Lillard, 2009)

Nanoparticle Types
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NPs have been developed using a variety of materials including metals,
ceramics and polymers (Abiodun-Solanke et al., 2014; Adeyemi & Sulaiman,
2015; De Jong & Borm, 2008; Wang & Wang, 2014). Silver NPs have been
widely used in dentistry to fabricate new materials like cements or resins (Arvizo
et al., 2012; Batra & Miglani; Ge et al., 2014; Batra et al. 2016). Magnetic NPs
like magnetite and maghemite, which are comprised of iron oxide, have been
actively studied for cancer and gene therapy applications (Gobbo et al., 2015;
Herranz et al., 2011; Batra et al. 2016, unpublished). Copper, zinc, titanium
dioxide and quaternary ammonia NPs have demonstrated antimicrobial activity
and their hydrophobic nature and surface charge add to their antimicrobial
activity (Batra et al. 2016, unpublished). Many of the metal-based NPs have
imparted antimicrobial properties that have proven beneficial to oral health by
improving the interaction of therapeutics with bacterial biofilms and inhibiting the
biofilm formation (Allaker, 2010; Senior et al., 2012; Sirelkhatim et al., 2015;
Batra et al., 2016). The proposed mechanism of these antibacterial activities is
believed to arise from an electrostatic attraction of positively-charged NPs with
the negative charge of the bacterial cell membrane (Palza, 2015; Singh & Lillard,
2009). Other novel systems using silica NPs and nitric oxide NPs are being
studied for to prevent biofilms as well (Kafshgari et al., 2014; Batra et al. 2016).
However, despite these attributes, there have been several concerns regarding
the toxicity associated with the metallic NPs and their accumulation in various
tissues and organs (Niazi & Gu, 2009). To avert the toxicity associated with metal
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NPs, polymeric NPs have the potential to offer a safer and more biocompatible
delivery method.

Polymeric NPs
Polymeric NPs have demonstrated biocompatibility and flexible tuning of physical
properties enabling the drug release and dosage profiles. There are many types
of polymeric NPs including poly (lactic acid) (PLA), poly(ε-caprolactone) (PCL),
polyethyleneimine, poly (lactic-co-glycolic acid) (PLGA) and poly (glycolic acid)
(PGA). These polymers have been extensively used to prevent oral biofilms due
to their biodegradability and biocompatibility (Allaker, 2010; Wang et al., 2016).
Furthermore, polymeric NPs comprised of PLA and PGA, have the ability to
degrade into relatively inert metabolic by-products, enabling safe and non-toxic
delivery of associated cargo.

PLGA Nanoparticles
PLGA NPs have been FDA-approved for use in human therapy which is one of
the primary reasons for extensive research using these particles (Makadia &
Siegel, 2011). PLGA can deliver hydrophilic and hydrophobic small molecules as
well as larger macromolecules due to its well described formulation protocols
(Martin-Banderas et al., 2013). PLGA NPs are being tested for use in
photodynamic therapy, which when introduced into a bacterial cell, release
singlet oxygen and free radicals to destroy bacterial cells (Li & Huh, 2014). In
other work, PLGA NPs that encapsulate methylene blue have demonstrated
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efficacy against Gram-positive as well as Gram-negative bacteria associated with
endodontic as well as periodontal infections (Klepac-Ceraj et al., 2011). In
addition to the attributes that encapsulation provides, PLGA NPs can be surfacemodified to provide specific targeting and enhanced therapeutic outcomes
(Makadia & Siegel, 2011). Advanced studies are still being done to impart
knowledge about the basic functionality of the PLGA NPs with various peptide
modifications, yet these are considered to be promising antimicrobials delivery
vehicles relative to less specifically-acting conventional therapeutics (Makadia &
Siegel, 2011).
Our preliminary studies have suggested that PLGA NPs that are surfacemodified with BAR peptide increase the effectiveness of peptide-mediated
inhibition of P. gingivalis-S. gordonii adherence. A possible mechanism by which
these NPs enhance the potency is by promoting a multivalent binding interface to
increase the avidity of BAR with P. gingivalis, or by delivering BAR at a higher
localized concentration to P. gingivalis. In fact, many studies have demonstrated
that multivalent interactions are more efficacious in increasing the avidity of
peptides relative to monovalent interactions (Figure 2) ( Wang et al., 2016). In
one study, a specific special multivalent effect was observed for polymeric NPs
displaying galactan, resulting in a significant increase in binding, relative to free
glycan (Bonduelle et al., 2016). In another study, multivalent targeting approach
was shown to have the potential to amplify AT1R (Angiotensin 1 Receptor)
blockade in the eye and concomitantly deliver a therapeutic payload into ocular
lesions choroidal vasculature (Hennig et al., 2015). Similar to these studies, we
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expect that the increase in potency of the surface modified NPs may be due to
the increase in the valency.

Figure 2 Comparison of monovalent and multivalent interactions. Multivalent interactions
are considerably stronger than the individual bonding of a corresponding number of
monovalent ligands to a multivalent receptor and are often used in biological systems.
Adapted from Prof. Dr. Rainer Haag research topics.

Drug delivery by binding to Immunoglobulins
Therapeutic drugs and proteins often suffer from short half-life; mainly due to
their small size or rapid clearance by enzymes. Genetic modification of these
drugs or proteins employing various techniques can improve the
pharmacokinetics by prolonging the half-life by either preventing excretion or
degradation in the body. Like albumin, certain immunoglobulins IgG1, IgG2 and
IgG4 also bind to the FcRn (neonatal Fc receptor) and thus have a long half-life
(Strohl, 2015). Similar to the fusion of albumin binding moieties, IgG binding
domains (IgBDs) can be fused to therapeutic proteins. Studies have shown
14

different IgBDs have different affinity for serum immunoglobulins resulting in
different half-lives. The longest half-life of 21 to 23 hours has been seen with the
C3 domain from Streptococcal Protein G (SPG-C3) when fused to recombinant
antibodies (Kontermann, 2016).

Various types of Fusion Proteins (Genetic fusion to Immunoglobulins)
In addition to evaluating multivalent NPs for the delivery of BAR peptide, we
designed antibody-fused peptides to evaluate the effect of BAR valency. The
antibodies acted as another carrier for the peptide. Relative to NPs, BAR fusion
proteins offer the attributes of smaller size and definitive conjugation, allowing us
to easily assess the impact of valency on increased binding and corresponding
potency. This fusion protein allows us to begin to assess the degree of valency
that is required to increase potency of the peptide to inhibit biofilms. Fusion of
proteins to the Fc region of IgG 1, 2 and 4 will impart longer half-lives due to
binding of FcRn (neonatal Fc Receptor) to Fc region and FcRn mediated
recycling. Examples of Fc fusion proteins include TNF receptor 2 (etanercept),
VEGF (vascular endothelial growth factor) receptor (aflibercept), IL-1 receptor
(rilonacept), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (abatacept,
belatacept) and others (Strohl, 2015). Etanercept was the first approved Fc
fusion protein. Fc fusion is also used to extend the half-lives of biologically active
proteins. Romiplostim, a thrombopoetin mimetic Peptide-Fc fusion protein is
approved for treating immune thrombocytopenia (Kontermann, 2016) . Alprolix
(Factor IX-Fc), a monomeric Fc fusion molecule, showed a terminal half-life of
57-83 hours which was approximately three times more than the half-life of other
15

formulations of Factor IX (Strohl, 2015). These fusion proteins and various others
like Dulaglutide (GLP-1-Fc fusion protein), Efraloctocog-α (Factor VIII fused to
IgG1 Fc), Corifollitropin-α (FSH-CTP fusion) have been approved for marketing
(Strohl, 2015). Broadly neutralizing monoclonal antibodies (bnMAbs) may offer
powerful tools as topical microbicides (Hamorsky et al., 2013). However, this
option is hampered due to expensive MAb bio manufacturing based on
mammalian cell culture. To address this issue, a new production system for
bnMAb VRC01 in Nicotiana benthamiana plants using a tobamovirus replicon
vector was developed (Hamorsky et al., 2013). Also, the production of antibodies
using the conventional IgG production is not very safe. This novel plant based
production system is being used for our experiments and employs a simple
manufacturing process, as opposed to the conventional system which utilizes
two separate vectors for H and L chain (Hamorsky et al., 2013). This provides a
more consistent and a stable production as it generated antibodies from a single
polypeptide (Hamorsky et al., 2013). We will use an IgG antibody fused to the
BAR peptide to test the inhibition of interaction between P. gingivalis and S.
gordonii and compare it with the soluble BAR peptide. In addition to the small
size of the Ab as compared with the NPs, another reason for us to use it in our
experiments is because it would allow us to be able to compare the number of
BAR molecules on the NPs of the lowest BAR concentration (8.9 µg/mg NPs) to
the number of BAR molecules (2 or 4) on the BAR-Fc fusion. It would help us to
determine whether or not there is a particular number of BAR molecules required
to show an increase in potency.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS

Our overall HYPOTHESIS is that BAR-NPs may interact with P. gingivalis with
higher valency than free soluble peptide, thereby increasing the avidity and
potency of the interaction. This hypothesis will be tested using two approaches.
The first will utilize BAR-modified NPs which can be functionalized with a high
peptide valency. The second approach will examine BAR-antibody fusions with
lower and more well-defined peptide valency. The Specific Aims are to:

SPECIFIC AIMS
1) Construct BAR-modified PLGA nanoparticles and determine whether NPs
promote multivalent interaction with P. gingivalis.
2) Construct BAR-antibody fusion proteins in dimer and tetramer forms and
determine if they function as more potent inhibitors of P. gingivalis adherence
relative to free peptide

17

CHAPTER 3
MATERIALS AND METHODS

Peptide Synthesis
The peptide containing a covalently attached biotin at its N-terminus was
synthesized by BioSynthesis, Inc. (Lewisville, TX) and was obtained with greater
than 85% purity. The peptide is comprised of residues 1167 to 1193 of the SspB
(Antigen I/II) protein sequence of S. gordonii. The BAR-Flc (Fluorescent BAR
peptide) and unlabeled biotin BAR peptide used in this study, is shown in Table
1. Both contain biotin (BTN) attached to the N-Terminus and were obtained in
lyophilized form.

Table 1 Sequence of BAR peptide.
Peptide Name

Peptide Sequence

BAR-Flc

( BTN )-LEAAPK-Kflc-VQDLLKKANITVKGAFQLFSOH

BAR

( BTN )-LEAAPKKVQDLLKKANITVKGAFQLFS-OH

To determine the amount of BAR peptide on the NP surface, we used the
fluorescent BAR peptide (BAR-Flc) which is synthesized by covalently attaching
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6-carboxyfluorescein (Flc) to the epsilon amine of the lysine residue that is
underlined in Table 1.

Growth of Bacterial Strains
P. gingivalis strain ATCC 33277 was grown in Trypticase soy broth (TSBY
medium) (Difco) supplemented with 0.5% (w/v) yeast extract, 1 μg/ml (final
concentration) menadione, and 5 μg/ml (final concentration) hemin. Twenty
milliliters of media was reduced for 24 hours under anaerobic conditions
consisting of 10% CO2, 10% H2, and 80% N2. Next, P. gingivalis was inoculated
into the medium and grown for 48 hours at 37°C under anaerobic conditions. S.
gordonii DL-1 was cultured aerobically without shaking in brain-heart infusion
(BHI) broth supplemented with 1% yeast extract for 16 hours at 37°C.

Avidin-Palmitic Acid Conjugation
To obtain BAR-modified PLGA NPs, the NP surfaces were modified with avidin
palmitate to subsequently attach biotinylated BAR. Avidin-palmitate was
conjugated as described by Fahmy and Saltzman (Fahmy et al., 2005). Briefly,
10 mg of avidin was dissolved in 1.2 ml of 2% sodium deoxycholate (NaDC) in
phosphate buffered saline (PBS) warmed to 37 °C. Palmitic acid-NHS (PA-NHS,
Sigma) was dissolved in 2% NaDC at 1 mg/ml and sonicated until well-mixed.
Eight hundred microliters of the 1 mg/ml PA-NHS (PA-N-hydroxysuccinamide
ester, Sigma) solution was added dropwise to the reaction vial, and reacted
overnight at 37 °C. The following day, the reaction was dialyzed in 1200 ml of
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0.15% NaDC in PBS heated to 37 °C with 3500 MWCO dialysis tubing to remove
free PA-NHS. The solution was dialyzed overnight at 37 °C, and dialysis cassette
contents were transferred to a storage vial and stored at 4 °C. Two milliliters of
the above made PA-NHS solution was added dropwise to the reaction vial
containing avidin, and reacted overnight at 37ºC. The following day, the reaction
was dialyzed in 1.2L of 0.15% (w/v) NaDC in PBS. This dialysis sink solution was
heated to 37ºC, and a 3500 molecular weight cut off (MWCO) dialysis tube was
used to remove free PA-NHS. After overnight dialysis at 37ºC, complexed avidinpalmitate was transferred to a storage vial from the dialysis cassette and stored
at 4ºC.

Nanoparticle Synthesis
Surface-modified avidin NPs were made using the oil-in-water (o/w) single
emulsion technique. On the first day, two 100 mg PLGA NP batches were each
dissolved in 2 ml DCM overnight. The next day, 2 ml of 5% (w/v) polyvinyl alcohol
(PVA) was mixed with 2 ml of 5 mg/ml avidin-palmitate and vortexed slowly.
PLGA-DCM solution was subsequently added dropwise to two tubes that
contained the previously mixed PVA-Avidin-Palmitate (4 ml) while vortexed at
slow speed, with subsequent ultrasonication (Figure 3).
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Figure 3 Oil-in-water single emulsion technique.

The DCM solvent was evaporated by adding the NP solution dropwise to 50 ml of
0.3% PVA and mixed for 3 hours. After evaporation, the solution was divided
between six tubes and centrifuged at 13,000 rpm for 10 minutes at 4C to wash
the NPs prior to peptide conjugation. The supernatant was discarded and the
pellet was suspended in 10 ml PBS. Each of the four tubes was incubated with 1
ml of BAR-Flc each at a different concentration for 1 hour. The concentrations
used were 8.9, 17.8, 35.5, 71, 142 and 284 µg BAR/mg NPs, dissolved in 1 ml
PBS, for a total of 10 ml reaction volume. After the reaction, NPs were
transferred to centrifuge tubes, washed with 20 ml PBS and centrifuged again.
The NPs were then suspended with 20 ml DI water and washed three times to
remove unbound peptide. After three washes, the NPs were suspended in 5 ml
of distilled water, transferred to a 10 ml cryotube, frozen in -80°C for 3 hours and
subsequently lyophilized. All NPs were stored at -20ºC after synthesis. The
surface-modified particles with unlabeled non-fluorescent BAR peptide were
synthesized similarly.
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Synthesis of BAR-Fc Fusion Protein
A gene fusion protein encoding the desired Ab fused to BAR was synthesized. A
chimeric rabbit human monoclonal antibody sequence was used that was
designed and constructed by Dr. Palmer’s team in the Owensboro Cancer
Research Program. A BAR-Fc fusion dimer (Fc) (Figure 4) was constructed in
which a signal peptide was fused to the BAR peptide, then fused to the IgG1
hinge and Fc region. The signal peptide is a naturally occurring secretion signal
that are meant to be transported out from the cells. Once it is secreted, the
protein is easy to purify. The hinge serves as a flexible spacer between the two
parts of the Fc fusion protein, allowing each part of the molecule to function
independently. Utilizing these motifs, enabled alterations in the fusion protein
valency. Human IgG1 displays high ADCC (Antibody-dependent cell-mediated
toxicity) and CDC (Complement dependent toxicity), and is the most suitable for
therapeutic use against pathogens and cancer cells.
For the dimer molecule, each Fc protein has two BAR peptide molecules
attached to it. In the case of the tetramer (Fc’) (Figure 5), the signal peptide fused
to the BAR peptide was additionally fused to both the light chain and heavy chain
in place of the rabbit VL and VH sequences, resulting in a valency of four
peptides conjugated to each Fc’ molecule.
The gene was delivered via the Tobamoviral vector into Nicotiana benthamiana
leaves. The leaf material, 5-7 days post-infiltration, was homogenized and the
protein was extracted and purified. Host kex2p protease was used for cleavage
to produce the antibodies in N. benthamiana plants.
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BAR peptide

Fc

Dimer Sequence:
MGKQMAALCGFLLVALLWLTPDVAHGLEAAPKKVQDLLKKANITVKGAFQLFSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGK

Figure 4: BAR-Fc fusion dimer (Fc) showing BAR peptide fused to IgG1 hinge and Fc
region. Rice alpha amylase signal peptide (light blue), BAR peptide (light orange),
Human IgG1 hinge + Fc (dark green)

BAR peptide
Light chain

Heavy chain

Tetramer Sequence:
MGKQMAALCGFLLVALLWLTPDVAHGLEAAPKKVQDLLKKANITVKGAFQLFSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSKD
STYSLSSTLTLSKADYEKHKVYACEVTHQGLRS
PVTKSFNRGECGGKRTIQDSATDTVDLGAELH
OURHOURSDDPPPTASDIGKRGGLEAAPKKVQDLLKKANITVKGAFQLFSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKR
VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLS
LSPGK

Figure 5 Fc’: BAR-Fc fusion tetramer having a full antibody molecule (Fc’) showing BAR
peptide fused to both constant light and constant heavy chain in place of variable light and
variable heavy chain. Rice alpha amylase signal peptide (light blue), BAR peptide (light
orange), Constant light chain (light green), KP6 propeptide sequence (dark yellow),
Constant heavy chain (dark red), Human IgG1 hinge + Fc (dark green).
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Fluorescence Assay
To measure the amount of BAR peptide that was conjugated to the NP surface, a
fluorescent binding assay was conducted. NPs were reacted with BAR-Flc as
described above. A 1 mg/ml solution of NPs in 1X PBS was made and one
hundred microliters of the suspension was added to 96-well black microtiter
plates in triplicate. The fluorescence was measured at excitation/emissions
wavelengths of 485 nm/535 nm, and the background fluorescence was
subtracted from the final fluorescence readings. The level of BAR associated
with the NP samples was determined by comparing fluorescence with a standard
curve of BAR-Flc. To obtain the standard curve of BAR-Flc, a serial dilution of 1
mg/ml BAR-FLC stock was mixed with buffer to generate a range of peptide
concentrations from 0.01 to 100 µg BAR peptide per ml.

Dual Species Biofilm Assay
Testing NP-BAR Inhibition
Cultures of P. gingivalis and S. gordonii were obtained as previously described.
S. gordonii DL-1 cells were harvested by centrifuging a 19 ml culture of S.
gordonii at 5600 rpm for 15 min. One milliliter was used to measure the initial
O.D. (optical density) of cells. The supernatant was discarded and the cell pellet
was suspended in 1 ml of 1X PBS. S. gordonii was labeled with 40 μl of 5 mg/ml
hexidium iodide (Molecular Probes, Eugene, OR) and incubated for 15 min at
room temperature on a rocker platform protected from light. After incubation, the
labeled samples were centrifuged at 10,000 rpm for 3 mins, the supernatant was
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discarded, and the cells were suspended in 1 ml of 1X PBS. Following this, the
O.D. was measured at 600 nm from twenty-fold diluted cultures of S. gordonii to
determine cell count. For all experiments, the optical density of S. gordonii cells
was adjusted to 0.8 for uniformity of the S. gordonii cell counts in each well. After
adjusting the optical density, 1 ml of S. gordonii cells was added to each well of
five 12-well culture plates containing a sterilized micro-coverslip. The cell culture
plates were wrapped in aluminum foil to protect the labeled cells from light and
placed on a rocker platform in the anaerobic chamber for 24 hours.
P. gingivalis cultures used for biofilm formation were optimized using a similar
approach. In short, 19 ml of P. gingivalis cells were centrifuged for 15 min at
5600 rpm and 1 ml was used to measure the initial O.D. The supernatant was
discarded and the cell pellet was suspended in 1 ml of pre-reduced 1X PBS. P.
gingivalis cells were labeled with 40 μl of 4 mg/ml carboxyfluorescein–
succinylester (Molecular Probes). Cells were incubated with the fluorescent dye
for 15 mins on a rocker platform and protected from light. Following incubation,
cells were centrifuged at 10,000 rpm for 3 min and the supernatant was
discarded to remove the unbound fluorescent dye. The pelleted cells were
suspended in 1ml of pre-reduced 1X PBS. The optical density of P. gingivalis
cells was adjusted to 0.4 for uniformity of the P. gingivalis cell counts in each
well.
For biofilm inhibition experiments, BAR-NPs, soluble BAR or avidin-only NPs
were pre-incubated with labeled P. gingivalis at 25°C for 30 min before
transferring to the appropriate wells. The NPs that were surface-modified with
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unlabeled BAR peptide were used for these experiments. For each batch of NPs
that were synthesized, using input concentrations of BAR of 71 µg BAR/mg NPs,
35.5 µg BAR/mg NPs, 17.8 µg BAR/mg NPs, or 8.9 µg BAR/mg NPs, five
different concentrations of BAR (0.3 µM, 0.7 µM, 1.3 µM, 2.0 µM, 2.5 µM) were
tested for biofilm inhibition. After calculating the amount of NPs required to
deliver the desired level of BAR peptide, one milliliter of each of these solutions
was added in triplicate to the culture plates. Molar equivalents of free BAR
peptide (0.3 µM, 0.7 µM, 1.3 µM, 2.0 µM, 2.5 µM) were also tested. Controls
comprised treating cells with PBS alone or with avidin-only NPs in triplicate. The
cell culture plates were covered with aluminum foil and incubated for 18-24 hours
in an anaerobic chamber.
Following incubation, the supernatant was removed from the wells of the cell
culture plates and the cells were washed with pre-reduced 1X PBS to remove
non-adherent bacterial cells. The cells were subsequently fixed with 4% (w/v)
paraformaldehyde, excess paraformaldehyde was removed, and the cells were
washed with pre-reduced 1X PBS. After washing, the coverslips were mounted
on a glass slide using Prolong Gold anti-fade reagent and viewed using confocal
laser scanning microscopy.

Testing BAR-Fc Fusion Inhibition
Biofilm inhibition by the purified BAR-Fc fusion protein was conducted similarly
as described above. Three different concentrations of the BAR-Fc fusion protein
were tested; 1 µM, 0.5 µM, and 0.25 µM, corresponding to 2.0 µM, 1.0 µM and
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0.5 µM equivalents of BAR, respectively, since each fusion protein contained two
molecules of BAR. Free BAR-peptide (unlabeled) at concentrations of 2.0 µM,
1.0 µM and 0.5 µM were tested. Control reactions consisted of treating cells with
PBS alone or with antibody that did not contain BAR.

Confocal Microscopy
P. gingivalis-S. gordonii biofilms were visualized using a Leica Microsystems
confocal laser scanning microscope (TCS SP8) and the Leica Application Suite X
software. The slides were viewed using an argon laser for visualization of FITClabeled P. gingivalis and the HeNe-G laser to visualize hexidium iodide-labeled
streptococci. P. gingivalis binding was determined from randomly chosen frames
using Leica Application Suite X Software. Z-stack images of the biofilms were
obtained using a z-step size of 0.7 μM and were constructed and analyzed using
the Volocity image analysis software.

Image Analysis
After obtaining biofilm images using confocal microscopy, the resulting z-stack
images were processed and reconstructed into 3D images using the Volocity
software. Images were imported into Volocity as multiple Tiff-files. Uniform filters
were used to remove noise from the images and were further analyzed to
quantify the extent of P. gingivalis binding. The image brightness and contrast
was adjusted equally for all frames, and a snapshot of the image was captured.
Next, the ratio of green to red fluorescence was determined. Each peptide
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concentration was analyzed in triplicate and 3 independent frames were
measured for each well. The mean and variation (SD) between samples was
determined using ANOVA. The variation was considered statistically significant
when P < 0.05.
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CHAPTER 4
RESULTS

Surface Modification Efficacy of PLGA NPs with BAR Peptide
A fluorescence assay was used to determine the amount of BAR peptide that
was bound to the surface of the NPs. Avidin-NPs were titrated with BAR peptide
at six different concentrations; 8.9, 17.8, 35.5, 71,142 and 284 µg BAR/mg NPs.
Previous experiments showed that a concentration of 142 µg BAR/mg NPs was
required to saturate the available avidin binding sites. However, in those
experiments 2 ml of 5 mg/ml avidin was used to modify 50 mg PLGA NPs during
synthesis. In the current experiments, 2 ml of 5 mg/ml avidin was used to modify
100mg PLGA NPs, resulting in half the modification density (per mg NP) used in
previous experiments. To measure the degree of modification, NPs were
incubated with various concentrations of BAR-Flc for 1 hour, washed, frozen, and
lyophilized. Fluorescence was measured as previously described. We observed
that the incorporation of BAR-Flc was directly related to the concentration of
BAR-Flc added. A standard curve (Figure 6) of soluble BAR-Flc was used to
quantify the output concentration of BAR.
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Figure 6 Standard Curve for free BAR peptide showing fluorescence at increasing BAR
amounts. This graph was used to calculate the BAR Flc output concentration for the
BAR-NPs. The x-axis is expressed in terms of the amount of BAR added per well (µg).
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Figure 7 Saturation curve for fluorescently labelled BAR. The input concentration of
BAR was varied and resulted in a dose-dependent amount of BAR conjugated to the NP
surface ranging from 1.48 to 5.87 µg BAR/mg NPs. We observed that above 71 µg
BAR/ mg NP (input concentration), the avidin sites on the NP surface were saturated
resulting in no additional conjugation to the NP surface.
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As shown in Figure 7, an input concentration of 71 µg/mg NPs resulted in
saturation, indicating that all available avidin binding sites were bound by biotinBAR peptide. Beyond this input concentration, additional peptide was not
conjugated to the NP surface.

Table 2 Correlation between the input concentration of BAR-FLC peptide and quantity of
BAR-FLC on the NP surface. Increasing amounts of BAR peptide resulted in increased
amounts of conjugated BAR. However, above 71 ug BAR/mg NP, the NP surface was
saturated as seen in Figure 7.

[Output:
[Input: Quantity of BAR-

Quantity of BAR-

Flc peptide (ug) reacted

Flc peptide (ug)

with surface of NPs (mg),

bound to

ug/mg]

surface of NPs

Sample

(mg), ug/mg]
A

284

5.87±0.48

B

142

5.69±0.95

C

71

5.66±0.20

D

35.5

2.90±0.16

E

17.8

1.48±0.17

F

8.9

1.20±0.68

Previous experiments showed incorporation of 1.5 nmol avidin per mg NP.
Assuming 4 binding sites per avidin, the maximal payload of BAR is 6 nmol per
mg NP (~22 g/mg NP). According to Table 2, after reacting the NP surface with
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71, 142, and 284 µg BAR/mg NPs, the NP surface was saturated with BAR
peptide, and bound approximately 5.7 g BAR per mg NP. This suggests that
26% of the avidin binding sites are available for interaction with BAR.

Biofilm Inhibition Assay with BAR-NPs
The biofilm inhibition and fluorescence binding assays were performed in parallel
to minimize experimental errors. As previously discussed, different
concentrations of BAR-NPs were evaluated to determine the effect of peptide
valency on P. gingivalis and S. gordonii inhibition. Streptococcal cells were
immobilized and P. gingivalis was incubated with S. gordonii for 18-24 hours. The
biofilms were visualized using confocal microscopy and the percent inhibition
was calculated by determining the ratio of S. gordonii to P. gingivalis cells using
Volocity. Previous studies showed that the IC50 (50% inhibitory concentration) of
soluble BAR was 1.3 µM; therefore, a range of BAR molar equivalents ranging
from 0.3 - 2.5µM was tested for each formulation of BAR-NPs (containing
payloads of 1.20, 1.48, 2.90 and 5.66 µg BAR/mg NP; see Table 2). For control
reactions, P. gingivalis was treated with defined concentrations of soluble BAR
(1.3, 2.0, and 2.5M) or avidin-NPs alone. P. gingivalis was also incubated with
S. gordonii in the presence of buffer alone. The corresponding biofilm images are
shown in Figures 8 and 9.
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Figure 8: BAR-NP inhibition of P. gingivalis (green cells) adherence to S. gordonii (red
cells). Biofilms were visualized by confocal microscopy and image stacks were
assembled using Volocity image analysis software. The concentrations indicated on the
images represent BAR peptide equivalents on the NP surface. As the surface density of
BAR on the NP surface decreases (left-to-right), a decrease in biofilm inhibition is
observed, indicated by the increased presence of P. gingivalis cells (green). Similarly, as
the molar equivalent of BAR peptide delivered by each NP formulation is decreased
(top-to-bottom), we observe a decrease in biofilm inhibition indicated by the increased
presence of P. gingivalis cells (green). This figure displays molar equivalents of BAR
ranging from 2.5 to 1.3 µM.
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Figure 9: BAR-NP inhibition of P. gingivalis (green cells) adherence to S. gordonii (red
cells). Biofilms were visualized by confocal microscopy and image stacks were
assembled using Volocity image analysis software. The concentrations indicated on the
images represent BAR peptide equivalents on the NP surface. As the surface density of
BAR on the NP surface decreases (left-to-right), a decrease in biofilm inhibition is
observed, indicated by the increased presence of P. gingivalis cells (green). Similarly, as
the molar equivalent of BAR peptide delivered by each NP formulation is decreased
(top-to-bottom), we observe a decrease in biofilm inhibition indicated by the increased
presence of P. gingivalis cells (green). This figure displays molar equivalents of BAR
ranging from 1.3 to 0.3 µM.

Robust formation of P. gingivalis/S. gordonii biofilms occurred in the PBS and
avidin-NP control reactions, whereas significant inhibition of biofilm formation
was seen when cells were incubated with the BAR-NP preparations. This
indicates that NPs without BAR have no effect of P. gingivalis adherence to
streptococci and subsequent biofilm formation and that inhibition of biofilm

34

formation can be attributed to BAR peptide delivered by NPs.

The biofilm images were organized horizontally from left to right (see Figures 8
and 9) with the NP formulation containing the highest payload of peptide (5.66
µg/mg NP) on the left and lowest payload (1.20 µg/mg NP) on the right. In each
vertical columns, the molar equivalent of BAR peptide delivered by each NP
formulation is decreased. As shown in Figures 8 and 9, the biofilm inhibition
increased with increasing BAR payload, even though each NP preparation
delivered the same molar equivalent of BAR peptide.
This suggests that BAR-NPs with higher payloads interact with P. gingivalis at
higher valency. In addition, as expected a dose dependent inhibition of biofilm
formation occurred as the molar equivalent of peptide delivered by the various
NP formulations was increased. Table 3 summarizes the percent biofilm
inhibition calculated for each NP formulation and for each molar equivalent of
BAR that was tested.
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Table 3 Maximum biofilm inhibition is observed for NPs functionalized with the highest
valency of BAR peptide. Biofilm inhibition decreases as a function of NP valency and
total BAR concentration.
Sample
[BAR] µM
% Inhibition
valency (µg
BAR/mg NPs)
5.66
2.5
94.15

2.90

1.48

1.20

2

92.00

1.3

88.6.0

0.7

61.82

0.3

30.70

2.5

80.96

2

77.91

1.3

75.45

0.7

39.93

0.3

29.41

2.5

68.30

2

65.08

1.3

63.58

0.7

40.48

0.3

24.71

2.5

59.83

2

52.92

1.3

43.12

0.7

17.05

0.3

14.93
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Figure 10 Biofilm inhibition curves showing BAR concentration versus percent inhibition
for each NP surface modification group. Percent inhibition for 5.66 (blue), 2.90 (orange),
1.48 (grey) and 1.20 (yellow) µg BAR/mg NP are shown.

Overall, the NPs with the highest peptide valency exhibited the lowest IC50 values
(Table 4). Conversely, as the valency of the BAR-NPs decreased, the IC50 value
increased (Figures 10 and 11). The BAR-NPs bound to P. gingivalis significantly
inhibited P. gingivalis-S.gordonii interaction as compared with PBS and avidinNPs controls (p<0.05).

To determine the number of peptides corresponding to NP valency for the
different formulations, the number of BAR peptides on each NP was calculated
as a function of NP size, diameter, peptide MW, and conjugation density. The
concentration of peptide conjugated per milligram NP: 5.66, 2.90, 1.48 and 1.20
µg BAR/mg NPs (Table 2), corresponded to 2140, 1089, 556 and 451 peptides
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per NP, respectively.

Table 4 As the input BAR concentration decreases,the IC50 increases
Sample
Input BAR
Output BAR
IC50 µM
concentration

concentration

µg/mg NPs

µg/mg NPs

A

71

5.66

0.56

B

35.5

2.90

0.74

C

17.8

1.48

0.91

D

8.9

1.20

1.81

2
1.8
1.6

IC 50

1.4
1.2
1
0.8

0.6
0.4
0.2
0
0

1

2

3

4

Input [BAR] µg/mg NPs
Figure 11 The lowest IC50 is achieved in the sample
with the highest valency of BAR peptide.
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5

6

Biofilm Inhibition Assay with BAR-Fc Fusion

The BAR-Fc fusion biofilm inhibition assay was conducted similar to the BAR-NP
experiment. The BAR-Fc fusion concentrations (dimer) used to determine biofilm
inhibition were 0.25, 0.5, and 1 µM BAR-Fc. For control reactions, P. gingivalis
was treated with defined concentrations of soluble BAR (0.5, 1.0 and 2 µM).
Control reactions consisted of P. gingivalis incubated with Ab alone or with buffer
alone. The biofilm images along with the controls are shown in Figure 12. In
addition to synthesizing the dimer fusion protein, we attempted to synthesize a
tetramer fusion protein. During the synthesis process, there were challenges in
the expression and purification of protein. Future experiments will seek to
address this issue.
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Figure 12 BAR-Fc inhibition of P. gingivalis adherence to S. gordonii. Biofilms were
visualized by confocal microscopy and image stacks were assembled using Volocity
image analysis software. Red cells represent S. gordonii and green cells represent P.
gingivalis. The concentrations indicated on the images represent BAR peptide equivalents
conjugated to the antibody.

Figure 12 shows that as the amount of BAR peptide is increased from 0.5 µM
(Ab=0.25µM) to 2 µM (Ab=1µM), there is a decrease in the number of P.
gingivalis cells (green cells) adhered to streptococci and increased inhibition of
biofilm formation. As shown in Table 5, a dose-dependent increase in the percent
inhibition of biofilm formation occurred as the amount of the BAR peptide
increased.
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Table 5 A BAR-Fc fusion protein containing two molar equivalents of BAR was
synthesized and tested against free peptide for biofilm inhibition. The table shows the
input BAR amount versus percent inhibition for increasing concentrations of peptide in
Ab-BAR fusion proteins. Percent inhibition was calculated by quantifying fluorescence of
the confocal images and plotted against the equimolar amounts of BAR peptide present
in each sample of the BAR-Ab fusion proteins. A dose-dependent response was
observed.
Input BAR
Sample
Percent Inhibition
amount (µM)
A

0.5

10.77

B

1.0

28.73

C

2.0

63.78

.

Table 6 shows that the IC50 for the Ab-BAR fusion peptide was approximately 1.6
µM which is similar to the IC50 of free BAR peptide. This indicates that for this
particular formulation, the Ab-BAR fusion peptide was not more potent than
soluble BAR peptide (p<0.05).

Table 6 The IC50 of interaction for the Ab-BAR Fusion protein was determined to be
1.61µM which is similar to that of free BAR peptide

Peptide

IC 50

BAR

1.3 µM

Ab-BAR Fusion

1.6 µM

*Daep C.A., R.J. Lamont and D.R. Demuth. 2008. 576
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CHAPTER 5
DISCUSSION

While the oral cavity accommodates both anaerobic and aerobic organisms, the
environment of the oral cavity poses an adverse environment for organism
survival (Dalwai et al., 2006). Due to the action of saliva, which reduces the
accumulation of bacteria by various mechanisms, the bacteria must struggle to
survive and stay in the oral cavity (Dalwai et al., 2006). To counteract the effects
of saliva, the initial colonization and adhesion of bacterial organisms to the tooth
surface occurs via the acquired pellicle (Lindh et al., 2014). Subsequent bacterial
adhesion and colonization occur with the help of contact-dependent signaling,
leading to the initiation and development of polymicrobial biofilms (Donlan, 2002).
These polymicrobial biofilms are comprised of a structured community of microorganisms that are adhered to the surface and enclosed in a self-generated
matrix. Interaction within these biofilms can be mutualistic, commensalistic or
antagonistic (Willems et al., 2016). These interactions contribute to the formation
of subgingival biofilms that stimulate a cascade of chronic inflammatory reactions
by the diseased tissue (Bao et al., 2014). Its initiation is attributed to the
formation of subgingival biofilms that stimulate a cascade of chronic inflammatory
reactions by the diseased tissue (Bao et al., 2014). Porphyromonas
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gingivalis, Tannerella forsythia and Treponema denticola are associated with the
occurrence and severity of the disease and are found as a part of these biofilms
(Bao et al., 2014). P. gingivalis is one of the ‘red’ complex bacteria and has been
suggested to function as a keystone pathogen (Darveau et al., 2012). P.
gingivalis can be cultivated easily and genetic tools are available to facilitate its
study (Suzuki et al., 2013). For these reasons P. gingivalis has been extensively
studied and is being targeted as a key organism to inhibit biofilm formation
(Darveau et al., 2012; Suzuki et al., 2013). Mechanistically, P. gingivalis is an
obligate anaerobe and its primary niche is the subgingival pocket, but before it
can establish itself there it must survive within the relative aerobic supragingival
pocket. To enable its survival, P. gingivalis interacts with a facultative anaerobe
S. gordonii supragingivally. This interaction is an initial event in biofilm formation,
and represents an ideal target to inhibit the colonization of P. gingivalis and
combat the initial stages of periodontitis. (Daep et al., 2008; Darveau et al., 2012;
Park et al., 2005).
The interaction between S. gordonii and P. gingivalis involves the Mfa1 of P.
gingivalis binding to the SspB of S. gordonii (Cook et al., 1998; Daep et al., 2006;
Park et al., 2005). Previous studies have suggested a specific region on SspB
that is involved in the interaction (Daep et al., 2006). This area has been
recognized as BAR (SspB Adhering Region) and studies have led to the
development of a peptide (BAR) which is derived from the antigen I/II protein of
S. gordonii ( Daep et al., 2006; Daep et al., 2008). BAR peptide has
demonstrated potent inhibition of P. gingivalis adherence to S. gordonii. BAR
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also significantly reduced P. gingivalis virulence in mice which harbored S.
gordonii and were subsequently inoculated with P. gingivalis. (Daep et al., 2011).
Additionally, BAR peptide proved potent in a dual-species biofilm; however, its
efficacy decreased in pre-formed and more complex biofilms, requiring increased
quantities and longer duration of peptide incubation (Gummadi, 2013,
unpublished). In efforts to improve potency and to achieve a concentrated dose
of BAR at the target site, surface-modified multivalent BAR-PLGA NPs were
constructed.
The consideration of multivalency in the design of therapeutic carriers has the
potential to enhance the inhibitory potential of low affinity molecules by
increasing the number of interactions and decreasing the dissociation rates
(avidity), between the delivery carrier and its therapeutic binding target.
(Chittasupho, 2012). Multivalent approaches have proven effective to block the
attachment of the influenza virus to its target cell by an inhibitor which is
multivalent (Mammen et al, 1998). Similarly, multivalent targeting approaches
amplified angiotensin II receptor type 1 blockade in the eye and concomitantly
deliver a therapeutic payload into ocular lesions. In this project we implemented
the concepts of multivalency to create high avidity interactions between the BARmodified NPs and the bacterial binding receptors. We hypothesized that carriers
with increased valency would increase the potency of the peptide (Chittasupho,
2012).

Nanoparticle technology has contributed to a variety of translational applications,
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demonstrating versatility and biocompatibility in the delivery of an assortment of
cargo, including drugs, genes, and proteins. Recently, NPs have found use in
various areas of restorative dentistry, minimally invasive dental procedures,
cancer diagnosis and treatment, molecular imaging and implant dentistry (Mantri
& Mantri, 2013). Due to their high structural integrity, stability during storage,
ease of preparation and functionalization, and controlled release capability,
polymeric NPs are highly attractive as drug delivery vehicles (Cheow & Hadinoto,
2014).
Recent studies employing NPs for oral applications, have shown that BAR-NPs
are more potent than the soluble BAR in inhibiting P. gingivalis adherence to S.
gordonii, and preventing biofilm formation (Steinbach-Rankins, Demuth,
unpublished). In this work, NPs were surface-modified with avidin to bind to the
biotin of the BAR peptide. Avidin-biotin-ligand conjugation is considered to be
one of the strongest non-covalent bonds and offers an efficient method of
attaching the peptide to the NP surface (Bratthauer, 2010; Howarth et al., 2006).
It was determined that each avidin has four biotin binding sites, but due to their
close proximity to each other, leading to steric hindrance, we assumed that only
two of the biotin-binding sites were available for biotinylated BAR conjugation
(Howarth et al., 2006; Steinbach et al., 2016). The mechanism by which the
PLGA-NPs enhanced the potency of the BAR peptide may be due to increased
localized concentration of the BAR peptide or by promoting a multivalent binding
interface to increase the avidity of BAR with P. gingivalis. In our experiments we
hypothesized that BAR-NPs increased the avidity of the interaction by increasing
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the valency of BAR, thereby increasing the potency relative to free BAR peptide.
We used two experimental assays to evaluate the efficacy as a function of
increased BAR valency. Biofilm inhibition assays were performed using BARNPs and BAR-Fc fusion proteins, and the percent inhibition of P. gingivalis to S.
gordonii adherence was compared to that of free BAR peptide.
First a direct approach was used to quantify the amount of BAR bound to the NP
surface. BAR-Flc was reacted with NPs at concentrations of: 8.9, 17.8, 35.5, 71,
142, and 284 µg BAR/mg NPs. We varied these concentrations around a threefold molar excess of BAR (71µg BAR/mg NPs) to available binding sites and
observed that at this concentration, all available avidin binding sites were
saturated on the NP surface. The percentage of BAR bound to the NPs, relative
to the input concentration remained constant (24%) even upon increased
concentrations of reactant BAR (e.g. 142 and 284 µg BAR/mg NPs). In
comparison with previous experiments, in which the same amount of avidin was
added to 100 mg versus 50 mg PLGA NPs, half the amount of BAR was needed
(71 vs. 142 µg) indicating that less avidin may be used during the synthesis
process to induce similar binding results. In our experiments, we achieved 1.20 ±
0.68, 1.48 ± 0.17, 2.90 ± 0.16, and 5.66 ± 0.20 µg BAR/mg NPs, bound to the NP
surface at input concentrations of 8.9, 17.8, 35.5, and 71 µg BAR/mg NPs,
respectively, demonstrating very efficient binding.
To determine if this increase in the binding efficiency was attributed to an
increase in valency, similar concentrations of BAR-NPs (8.9, 17.8, 35.5, 71, 142,
and 284 µg BAR/mg NPs) were reacted with P. gingivalis. P. gingivalis cells

46

were subsequently incubated with immobilized S. gordonii to form biofilms. Five
different equimolar BAR peptide concentrations (0.3, 0.7, 1.3, 2.0, and 2.5 µM)
for each batch of BAR-NPs (with differing valency) were evaluated. As the
equimolar BAR NP concentration increased, biofilms were increasingly inhibited
and P. gingivalis to S. gordonii interaction decreased. We also found out that the
50% inhibitory concentration was highest for the BAR-NP sample that had the
maximum BAR density (valency) on the NP surface.
Next, we used a different platform to deliver BAR peptide – a BAR -Ab fusion
protein. IgG was used in a dimer form and BAR peptide was fused to it using a
novel plant based production platform, with one molecule of antibody carrying
two molecules of BAR (Hamorsky et al., 2013). The biofilms were formed using a
concentration range of BAR: 0.5 µM (Ab=0.25µM), 1 µM (Ab=0.5 µM), and 2 µM
(Ab=1µM), and biofilm inhibition was quantified. Although a linear increase in the
percent inhibition was observed as the amount of BAR peptide increased, the
IC50 (1.6 M) was similar to that of free BAR alone (IC50=1.3µM). Hence, to make
the BAR-Fc fusion more potent, we believe that more BAR molecules need to be
fused per Ab molecule. As we calculated before, 451 molecules of BAR are
present per NP in 8.9 µg BAR/mg NP (lowest valency) batch as compared to 2
molecules in a BAR-Fc fusion, it is not surprising that we did not see an increase
in potency of BAR in BAR-Fc fusion proteins. Our data, therefore, suggests that
increased number of BAR molecules are required to improve the fusion protein
potency. We also speculate that if the tetramer form of BAR-Fc fusion (Fc’) were
to be tested, we would not have been able to observe an increase in the potency
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of that particular formulation as we believe that more than 2 but less than 451
molecules of BAR are required to achieve the desired effect. This comparison
highlights differences between platforms that enable low, relative to high density
modification; however, we acknowledge that there are likely differences in
available BAR spatial arrangements between NP and Ab carriers. Therefore,
even equivalent amounts of BAR on each carrier may exhibit dissimilar effects in
binding, due to platform differences.
This concept of the increased percent inhibition due to an increase in valency,
provides us a solid framework to develop therapeutics, by designing NPs to
specifically target microorganisms more effectively and safely. As recent studies
suggest that P. gingivalis plays a significant role in altering the host-microbe
homeostasis, new delivery platforms for BAR peptide seek to block P. gingivalis
interactions more effectively. We understand that the etiology of periodontitis is
very complex and there might be many more bacterial interactions
simultaneously involved, which might have significant impact on disease
progression. The surface-modified NPs could, therefore, be applied to target
other bacterial interactions in the oral cavity and combat the bacterial
colonization, thereby, periodontitis. This could be achieved by modifying the NPs
with peptides pertaining to particular interactions.
The experimental results suggest that by increasing NP valency, we can obtain
increased avidity and potency of the peptide. This paves the way for lower
concentrations of BAR to be used, while still achieving similar efficacy. Constant
flow of saliva in the oral cavity and the intake of food and water may regularly
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wash out the therapeutic peptides (BAR) which would decrease the effectiveness
of BAR. Due to the efficacy of BAR-NPs at both high and low concentrations,
relative to free BAR peptide, this approach may prove very beneficial. Since BAR
peptide is relatively expensive to produce, this method of conjugating BAR to
NPs may offer a more cost effective alternative for delivery. Additionally, because
of the conjugation with NPs, BAR can be delivered locally in a concentrated form
to increase BAR effectiveness. For translational applications, BAR-modified NPs
may, eventually, be prescribed as mouthwashes or chewing gums after oral
prophylaxis procedures done in a dental office. This would offer a cure for
periodontitis and not just a preventive treatment like scaling or gingival surgery.

We are still establishing effect of BAR-modified NPs on pre-formed and more
complex biofilms. Future directions of this research project will study the effect of
BAR-NPs in established biofilms as well as in more complex biofilms with
Fusobacterium nucleatum, in vitro. From a design perspective, decreased avidin
reactant may be used for conjugation to the NP surface, which may further
increase the potency of the BAR peptide. Experiments will also be conducted to
determine the toxicity of surface-modified NPs in human gingival cells, with
eventual translation to animal models. Regarding BAR-Fc fusion proteins,
additional modifications of the non-Fc binding BAR Abs will be pursued to
enhance their therapeutic potential. For example, they may be constructed in
tetramer or higher valency forms, which would incorporate four or more
molecules for BAR per molecule of Ab. These formulations may prove promising
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for inhibition. To benefit from both delivery technologies, we may investigate AbBAR-NPs, to enhance and prolong effects in the oral cavity. Our long-term goal is
to develop a therapeutic that can be approved to be tested in clinical trials. We
envision that clinical trials will require recognizing that the oral cavity is a niche
for many organisms. This would involve creating conditions that would harbor
only the bacteria that need to be studied. We envision that clinical prevention and
treatment may involve the administration of BAR peptide immediately after oral
prophylaxis. With this, the number of P. gingivalis cells that recolonize the oral
cavity with time can be used as an outcome to assess the efficacy of BAR-NP
preparations. For example, one possible approach is to subject patients to oral
prophylaxis and then provide one group with a mouth rinse containing BAR-NPs
and a second group with a placebo formulation. The kinetics of P. gingivalis
recolonization would serve as the outcome to determine the effectiveness of the
treatment protocol. In these experiments, patient compliance must be monitored
very carefully. Overall, BAR-NPs look very promising and may pave the way to
develop therapeutics that would actually prevent biofilms from forming and
thereby reducing the incidence of chronic periodontitis.
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